MMP9 and gastroesophageal junction adenocarcinoma: Andecaliximab (GS-5745, a monoclonal antibody targeting MMP9) had been evaluated in several clinical trials for indications including advanced gastric and gastroesophageal junction adenocarcinoma (37) and advanced pancreatic adenocarcinoma (38).